<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04627402</url>
  </required_header>
  <id_info>
    <org_study_id>2020KYPJ127</org_study_id>
    <nct_id>NCT04627402</nct_id>
  </id_info>
  <brief_title>Effects of Adding Triamcinolone Acetonide to Conbercept Treatment for Refractory Diabetic Macular Edema (CONTE)</brief_title>
  <acronym>CONTE</acronym>
  <official_title>Effects of Adding Triamcinolone Acetonide to Conbercept in Diabetic Macular Edema With Limited Response to Anti-VEGF Treatment After One Injection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhongshan Ophthalmic Center, Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhongshan Ophthalmic Center, Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aimed to compare intravitreous conbercept alone with conbercept plus intravitreous&#xD;
      triamcinolone acetonide in DME eyes which showed limited response to anti-VEGF treatment&#xD;
      after one injection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Some eyes with diabetic macular edema (DME) were not sensitive to anti-vascular endothelial&#xD;
      growth factor (anti-VEGF) therapy and required continuous injections. Delayed control of&#xD;
      macular edema might cause irreversible function loss. To predict the response to anti-VEGF&#xD;
      treatment according to the CST change after one injection was proved reasonable recently.&#xD;
      Adding intravitreous corticosteroids to the treatment regimen at early time might result in&#xD;
      better outcomes than anti-VEGF therapy alone. Patients with diagnosis of refractory diabetic&#xD;
      macular edema, confirmed by fluorangiography and optical coherence tomography (OCT), with&#xD;
      limited response to one intravitreal anti-VEGF injection will be enrolled in the study. The&#xD;
      enrolled patients will be randomized for the addition or not of the triamcinolone to&#xD;
      intravitreal therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 12, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Diabetic macular edema.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Macular thickness</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in mean central subfield thickness from randomization visit measured with optical coherence tomography.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best-corrected visual acuity (BCVA)</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change in BCVA letter score from randomization visit as measured by the Early Treatment Diabetic Retinopathy Study (ETDRS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment number</measure>
    <time_frame>48 weeks</time_frame>
    <description>The number of intravitreous injection treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of complications</measure>
    <time_frame>48 weeks</time_frame>
    <description>The incidence of cataract and glaucoma</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Macular Edema</condition>
  <arm_group>
    <arm_group_label>Injection combo agents</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravitreous injection of triamcinolone acetonide (TA) and conbercept.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Injection single agent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravitreous injection of conbercept only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conbercept and TA</intervention_name>
    <description>Intravitreous injection of Conbercept and TA</description>
    <arm_group_label>Injection combo agents</arm_group_label>
    <other_name>Combined agents</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conbercept</intervention_name>
    <description>Intravitreous injection of Conbercept</description>
    <arm_group_label>Injection single agent</arm_group_label>
    <other_name>Single agent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type II diabetes&#xD;
&#xD;
          -  Vison decrease was mainly caused by diabetic macular edema (DME)&#xD;
&#xD;
          -  BCVA of 20/800 to 20/40 (decimal)&#xD;
&#xD;
          -  Central subfield retinal thickness (CST) ≥ 300μm by optical coherence tomography (OCT)&#xD;
             in the study eye&#xD;
&#xD;
          -  Pan-retinal photocoagulation finished at least 3 months ago, or no pan-retinal&#xD;
             photocoagulation is expected in the next 6 months&#xD;
&#xD;
          -  Within the last 3 months, one intravitreous injection of anti-VEGF agent was&#xD;
             performed, the CST reduction one month after injection was ≤ 20%.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-DME related macular edema, or edema control would not benefit the vision (for&#xD;
             example, macular atrophy)&#xD;
&#xD;
          -  Exist of other reasons of macular edema, retinal vein occlusion, uveitis, iris&#xD;
             rubeosis, high myopia&#xD;
&#xD;
          -  Ocular media opacity of insufficient quality to obtain OCT images and fundus images in&#xD;
             the study eye&#xD;
&#xD;
          -  Intraocular or periorbital injection of steroids within the last 3 months&#xD;
&#xD;
          -  Macular grid photocoagulation within the last 4 months&#xD;
&#xD;
          -  History of vitrectomy&#xD;
&#xD;
          -  History of scleral buckle within the last 4 months, or intraocular surgery is expected&#xD;
             in the next 6 months&#xD;
&#xD;
          -  Any sign of ocular infection, including conjunctivitis, hordeolum, dacryocystitis&#xD;
&#xD;
          -  Myocardial infarction, heart failure, stroke, or transient ischemic attack within one&#xD;
             month&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Uncontrolled hypertension, or blood pressure &gt;180/110&#xD;
&#xD;
          -  Patients with uncontrolled hyperglycemia, or Hemoglobin A1C (HbA1c) ≥10.0%, or under&#xD;
             hemodialysis , or started insulin usage within the last 4 months, or expected to start&#xD;
             insulin use for hyperglycemia control in the next 4 months&#xD;
&#xD;
          -  Those cannot follow visits on time&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bingqian Liu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhongshan Ophthamic Center, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qiuyi Liang, BS</last_name>
    <phone>+86 20 66683995</phone>
    <email>liubq6@mail.sysu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongshan Opthalmic Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiuyi Liang, BS</last_name>
      <phone>+86 20 66683995</phone>
      <email>liubq6@mail.sysu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Bingqian Liu, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Maturi RK, Glassman AR, Liu D, Beck RW, Bhavsar AR, Bressler NM, Jampol LM, Melia M, Punjabi OS, Salehi-Had H, Sun JK; Diabetic Retinopathy Clinical Research Network. Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial. JAMA Ophthalmol. 2018 Jan 1;136(1):29-38. doi: 10.1001/jamaophthalmol.2017.4914.</citation>
    <PMID>29127949</PMID>
  </results_reference>
  <results_reference>
    <citation>Neto HO, Regatieri CV, Nobrega MJ, Muccioli C, Casella AM, Andrade RE, Maia M, Kniggendorf V, Ferreira M, Branco AC, Belfort R Jr. Multicenter, Randomized Clinical Trial to Assess the Effectiveness of Intravitreal Injections of Bevacizumab, Triamcinolone, or Their Combination in the Treatment of Diabetic Macular Edema. Ophthalmic Surg Lasers Imaging Retina. 2017 Sep 1;48(9):734-740. doi: 10.3928/23258160-20170829-08.</citation>
    <PMID>28902334</PMID>
  </results_reference>
  <results_reference>
    <citation>Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, Schlottmann PG, Rundle AC, Zhang J, Rubio RG, Adamis AP, Ehrlich JS, Hopkins JJ; RIDE and RISE Research Group. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013 Oct;120(10):2013-22. doi: 10.1016/j.ophtha.2013.02.034. Epub 2013 May 22.</citation>
    <PMID>23706949</PMID>
  </results_reference>
  <results_reference>
    <citation>Shah AR, Yonekawa Y, Todorich B, Van Laere L, Hussain R, Woodward MA, Abbey AM, Wolfe JD. Prediction of Anti-VEGF Response in Diabetic Macular Edema After 1 Injection. J Vitreoretin Dis. 2017 May;1(3):169-174. doi: 10.1177/2474126416682569. Epub 2017 Feb 1.</citation>
    <PMID>29104958</PMID>
  </results_reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 29, 2020</study_first_submitted>
  <study_first_submitted_qc>November 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2020</study_first_posted>
  <last_update_submitted>November 14, 2020</last_update_submitted>
  <last_update_submitted_qc>November 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhongshan Ophthalmic Center, Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Bingqian Liu</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>diabetic macular edema; conbercept; triamcinolone acetonide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

